Best Clinical Research Paper 2018
Dr. Gregorc awarded by the San Raffaele Hospital
Ultraspecialisti is proud to divulge the great goal achieved by its co-founder, Dr. Gregorc Vanesa, Head of Thoracic Oncology, Melanoma and head-neck area, and adjunct professor, of San Raffaele Hospital in Milan.
Recently, in fact, the scientific committee of the Hospital has chosen to award her with the “Best Clinical Research Paper 2018“, an award addressed to the best scientific clinical publication of the year, of the whole Institute. An award she has deeply felt, the result of over ten years of study focused on a very important pathology such as mesothelioma, which still causes “slaughter" of patients in the environmental and professional context.
The study in question, of an international nature, assessed the therapeutic benefit of a new drug created at the San Raffaele Hospital for the treatment of this disease, with a strong social impact.
Dr. Gregorc, a strong supporter of digital innovation in the medical – health field, has followed all the research phases, supported by a large team of doctors and experts with whom she was able to share the precious result.
The award is recognized every year by the Hospital which is also an Institute of Hospitalization and Care of a Scientific Character, a hospital of excellence and research, clinical and translation research, in the biomedical field and in the organization and management of health services, high-quality hospitalization and care services; among the first in Italy can boast the primacy in scientific publications, a scenario of high complexity and competition, which gives credibility to the ten-year work carried out by Dr.Gregorc.
Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O’Brien M, NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomized, double-blind, placebo-controlled phase 3 trial, Lancet Oncology, 2018, 19(6): 799-811